• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

John Castiglia, MD, Senior Vice President and Chief Medical Officer, Premera Blue Cross


A unique collaboration among Premera Blue Cross, its pharmacy benefits manager, Medco, and its DM provider, Healthways, drives the Faster ID initiative, which aims to identify potential DM-program participants quickly.

John Castiglia, MD
Senior Vice President, Chief Medical Officer
Premera Blue Cross
Seattle, Wash.

MHE research indicates it takes about 100 days to identify and contact members who would benefit from DM programs; however, Faster ID takes an average of 8 to 10 days.

Dr. Castiglia would like to see earlier identification of more members with other DM needs and believes that Faster ID is an important component of Premera's arsenal, along with wellness and care management, in improving care and member health. "The approach is a win-win situation for everyone," he says.

Prior to coming to Premera, Dr. Castiglia served as vice president of healthcare services for Regence Blue Shield, where he also served as vice president of medical management and as medical director. Previously, he was senior medical director for FHP. He earned a B.S. degree in zoology from Ohio State University, his medical degree from the Medical University of Ohio at Toledo and an MBA from Arizona State University.

Related Content
© 2024 MJH Life Sciences

All rights reserved.